Key Metrics
CiteScore 

5.1
Impact Factor 

< 5
SNIP 

1.19
Recommended pre-submission checks
Powered by 

Topics Covered on Journal of Aerosol Medicine and Pulmonary Drug Delivery
Journal of Aerosol Medicine and Pulmonary Drug Delivery Journal Specifications
| Overview | |
| Publisher | MARY ANN LIEBERT, INC |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 2008 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Journal of Aerosol Medicine and Pulmonary Drug Delivery ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Journal of Aerosol Medicine and Pulmonary Drug Delivery
<i>Letter:</i> Revisiting NAC’s Multifaceted Role in Asthma Management: A Delicate Balance Between Anti‐Inflammatory Potential and Airway Defense Attenuation
- 27 Nov 2025
- Journal of Aerosol Medicine and Pulmonary Drug Delivery
Lung Deposition of Tanimilast, an Inhaled Phosphodiesterase-4 Inhibitor, in Patients with Asthma or COPD, Evaluated Using Functional Respiratory Imaging.
- 14 Nov 2025
- Journal of aerosol medicine and pulmonary drug delivery
Preclinical Studies of Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease.
- 24 Oct 2025
- Journal of aerosol medicine and pulmonary drug delivery
Letter: Comment on "Association of Inhaled Corticosteroid Use with COVID-19 Severity and Hospitalization in Patients with and Without Respiratory Disease".
- 1 Oct 2025
- Journal of aerosol medicine and pulmonary drug delivery
Richard William Fuller-The Clinical Scientist Behind the Development of Multiple Leading Inhaled Therapies for Asthma (b. June 29, 1953-d. 2024).
- 1 Oct 2025
- Journal of aerosol medicine and pulmonary drug delivery
Letter: Response to Comment on "Association of Inhaled Corticosteroid Use With COVID-19 Severity and Hospitalization in Patients With and Without Respiratory Disease".
- 1 Oct 2025
- Journal of aerosol medicine and pulmonary drug delivery
<i>Letter:</i> Revisiting NAC’s Multifaceted Role in Asthma Management: A Delicate Balance Between Anti‐Inflammatory Potential and Airway Defense Attenuation
- 27 Nov 2025
- Journal of Aerosol Medicine and Pulmonary Drug Delivery
Lung Deposition of Tanimilast, an Inhaled Phosphodiesterase-4 Inhibitor, in Patients with Asthma or COPD, Evaluated Using Functional Respiratory Imaging.
- 14 Nov 2025
- Journal of aerosol medicine and pulmonary drug delivery
Preclinical Studies of Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease.
- 24 Oct 2025
- Journal of aerosol medicine and pulmonary drug delivery
Letter: Comment on "Association of Inhaled Corticosteroid Use with COVID-19 Severity and Hospitalization in Patients with and Without Respiratory Disease".
- 1 Oct 2025
- Journal of aerosol medicine and pulmonary drug delivery
Richard William Fuller-The Clinical Scientist Behind the Development of Multiple Leading Inhaled Therapies for Asthma (b. June 29, 1953-d. 2024).
- 1 Oct 2025
- Journal of aerosol medicine and pulmonary drug delivery
Letter: Response to Comment on "Association of Inhaled Corticosteroid Use With COVID-19 Severity and Hospitalization in Patients With and Without Respiratory Disease".
- 1 Oct 2025
- Journal of aerosol medicine and pulmonary drug delivery